Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.
Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J. Angelini PD, et al. Among authors: giralt j. Cancer Res. 2013 Jan 1;73(1):450-8. doi: 10.1158/0008-5472.CAN-12-2301. Cancer Res. 2013. PMID: 23288917
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Albanell J, et al. Among authors: giralt j. Cancer Res. 2001 Sep 1;61(17):6500-10. Cancer Res. 2001. PMID: 11522647
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.
Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B, Keränen SR, Bateman A, Hickish T, Tabernero J, Thomas J, Brown G, Oates J, Chau I. Sclafani F, et al. Among authors: giralt j. Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):303-12. doi: 10.1016/j.ijrobp.2015.03.038. Epub 2015 Apr 4. Int J Radiat Oncol Biol Phys. 2015. PMID: 26031368 Clinical Trial.
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. Bonner JA, et al. Among authors: giralt j. Eur J Cancer. 2016 Sep;64:1-11. doi: 10.1016/j.ejca.2016.05.008. Epub 2016 Jun 17. Eur J Cancer. 2016. PMID: 27323346 Free PMC article. Clinical Trial.
Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.
Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, Baselga J. Bonner J, et al. Among authors: giralt j. JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):842-9. doi: 10.1001/jamaoto.2016.1228. JAMA Otolaryngol Head Neck Surg. 2016. PMID: 27389475 Free PMC article. Clinical Trial.
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumour Therapy (TTD). Rivera F, et al. Among authors: giralt j. Cancer Chemother Pharmacol. 2011 Jan;67(1):75-82. doi: 10.1007/s00280-010-1285-1. Epub 2010 Mar 3. Cancer Chemother Pharmacol. 2011. PMID: 20198372 Clinical Trial.
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Alsina M, et al. Among authors: giralt j. Target Oncol. 2018 Feb;13(1):69-78. doi: 10.1007/s11523-017-0536-z. Target Oncol. 2018. PMID: 29128908 Clinical Trial.
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Alsina M, et al. Among authors: giralt j. Target Oncol. 2018 Feb;13(1):79. doi: 10.1007/s11523-017-0544-z. Target Oncol. 2018. PMID: 29243205 Free article.
131 results